CoChat

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients

Boulenger, J.-P., Huusom, A. K. T., Florea, I., Bækdal, T., Sarchiapone, M. · 2006 · Current Medical Research and Opinion
Cited by 110

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objective: This randomised, double-blind, fixed-dose study evaluated the efficacy of escitalopram and paroxetine in the long-term treatment of severely depressed patients with major depressive disorder (MDD).Research design and methods: Patients with a primary diagnosis of MDD and baseline Montgomery-Åsberg Depression Rating Scale (MADRS) ≥ 30 were randomised to 24 weeks of double-blind treatment with fixed doses of either escitalopram (20 mg) (n = 232) or paroxetine (40 mg) (n = 227). The primary analysis of efficacy was an analysis of covariance (ANCOVA) of change from baseline to endpoint (Week 24) in MADRS total score (last observation carried forward, LOCF).Main outcome measures; results: At endpoint (24 weeks), the mean change from baseline in MADRS total score was –25.2 for patients treated with escitalopram (n = 228) and –23.1 for patients with paroxetine (n = 223), resulting in a difference of 2.1 points ( p < 0.05). The difference in the change in the MADRS total score (LOCF) was significantly in favour of escitalopram from Week 8 onwards. The proportion of remitters (MADRS ≤ 12) after 24 weeks was 75% for escitalopram and 67% for paroxetine ( p < 0.05). The results on the primary efficacy scale were supported by significantly greater differences in favour of escitalopram on the Hamilton Anxiety, Hamilton Depression and Clinical Global Impression-Improvement and -Severity scales. For very severely depressed patients (baseline MADRS ≥ 35), there was a difference of 3.4 points at endpoint in the MADRS total score in favour of escitalopram ( p < 0.05). The overall withdrawal rate for patients treated with escitalopram (19%) was significantly lower than with paroxetine (32%) ( p < 0.01). The withdrawal rate due to adverse events was significantly lower for escitalopram (8%) compared to paroxetine (16%) ( p < 0.05). There were no significant differences in the incidence of individual adverse events during treatment.Conclusion: Escitalopram is significantly more effective than paroxetine in the long-term treatment of severely depressed patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1185/030079906x115513

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 110

Metadata

Authors
Boulenger, J.-P., Huusom, A. K. T., Florea, I., Bækdal, T., & Sarchiapone, M.
Venue
Current Medical Research and Opinion
Published
2006-06-07
Volume
22
Issue
7
Pages
1331-1341
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2055897579
Cited by
110
References
6
FWCI
8.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. https://app.cochat.ai/papers/10.1185/030079906x115513
The paper
Boulenger, J.-P., Huusom, A. K. T., Florea, I., Bækdal, T., & Sarchiapone, M. (2006). A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Current Medical Research and Opinion. https://doi.org/10.1185/030079906x115513

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.